{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:14:23Z","timestamp":1762377263283},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Jagiellonian University Medical College, Cracow, Poland","award":["N41\/DBS\/000032; N41\/DBS\/000665; K\/ZDS\/006104","K\/ZDS\/003761; K\/ZDS\/006105"],"award-info":[{"award-number":["N41\/DBS\/000032; N41\/DBS\/000665; K\/ZDS\/006104","K\/ZDS\/003761; K\/ZDS\/006105"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pleiotropic effects have been implicated in clinical benefits of ticagrelor compared to thienopyridine P2Y<jats:sub>12<\/jats:sub> antagonists. There are conflicting data regarding effects of ticagrelor vs. thienopyridine P2Y<jats:sub>12<\/jats:sub> blockers on endothelial function. Our aim was to compare endothelial biomarkers and their relations with platelet reactivity in real-world patients after acute coronary syndrome (ACS) on maintenance dual antiplatelet therapy (DAPT) with ticagrelor or clopidogrel stratified by diabetes status.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Biochemical indices of endothelial dysfunction\/activation and platelet reactivity by multiple electrode aggregometry were compared in 126 stable post-ACS subjects (mean age: 65\u2009\u00b1\u200910\u00a0years, 92 men and 34 women), including patients with (n\u2009=\u200961) or without (n\u2009=\u200965) coexistent type 2 diabetes (T2DM) on uneventful maintenance DAPT with either ticagrelor (90\u00a0mg b.d.) or clopidogrel (75\u00a0mg o.d.) in addition to low-dose aspirin. Exclusion criteria included a complicated in-hospital course, symptomatic heart failure, left ventricular ejection fraction\u2009&lt;\u200940% and relevant coexistent diseases except for well-controlled diabetes, mild renal insufficiency or hypertension.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Clinical characteristics were similar in patients on ticagrelor (n\u2009=\u200962) and clopidogrel (n\u2009=\u200964). The adenosine diphosphate-induced platelet aggregation and circulating soluble P-selectin (sP-selectin) were decreased in ticagrelor users irrespective of T2DM status (p\u2009&lt;\u20090.001 and p\u2009&lt;\u20090.01 for platelet reactivity and sP-selectin, respectively). Plasma levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) were lower in T2DM subjects on ticagrelor vs. clopidogrel (758\u2009\u00b1\u2009162 vs. 913\u2009\u00b1\u2009217\u00a0\u00b5g\/L, p\u2009&lt;\u20090.01). In contrast, plasma sVCAM-1 was similar in non-diabetic patients on ticagrelor and clopidogrel (872\u2009\u00b1\u2009203 vs. 821\u2009\u00b1\u2009210\u00a0\u00b5g\/L, p\u2009&gt;\u20090.7). The concentrations of sE-selectin, monocyte chemoattractant protein-1 and asymmetric dimethylarginine did not differ according to the type of P2Y<jats:sub>12<\/jats:sub> antagonist regardless of T2DM status. Platelet reactivity was unrelated to any endothelial biomarker in subjects with or without T2DM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our preliminary findings may suggest an association of ticagrelor-based maintenance DAPT with favorable endothelial effects compared to clopidogrel users in stable post-ACS patients with T2DM. If proven, this could contribute to more pronounced clinical benefits of ticagrelor in diabetic subjects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-022-01685-4","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T12:03:54Z","timestamp":1668686634000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Endothelial biomarkers and platelet reactivity on ticagrelor versus clopidogrel in patients after acute coronary syndrome with and without concomitant type 2 diabetes: a preliminary observational study"],"prefix":"10.1186","volume":"21","author":[{"given":"Bernadeta","family":"Chyrchel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Kruszelnicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Surdacki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"issue":"2","key":"1685_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsk\u00fd P, ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119\u201377.","journal-title":"Eur Heart J"},{"issue":"14","key":"1685_CR2","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, J\u00fcni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM, ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289\u2013367.","journal-title":"Eur Heart J"},{"issue":"11","key":"1685_CR3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357.","journal-title":"N Engl J Med"},{"issue":"13","key":"1685_CR4","first-page":"1274","volume":"373","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP, Braunwald E, Sabatine MS. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;373(13):1274\u20135.","journal-title":"N Engl J Med"},{"issue":"24","key":"1685_CR5","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","volume":"31","author":"S James","year":"2010","unstructured":"James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, Maya J, Nicolau JC, Spinar J, Storey RF, Stevens SR, Wallentin L, for the PLATO Study Group. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010;31(24):3006\u201316.","journal-title":"Eur Heart J"},{"issue":"23","key":"1685_CR6","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","volume":"67","author":"DL Bhatt","year":"2016","unstructured":"Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, Im K, Murphy SA, Held P, Braunwald E, Sabatine MS, Steg PG. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016;67(23):2732\u201340.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1685_CR7","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1161\/CIRCULATIONAHA.109.913376","volume":"123","author":"JL Ferreiro","year":"2011","unstructured":"Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 2011;123(7):798\u2013813.","journal-title":"Circulation"},{"issue":"1","key":"1685_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12933-022-01581-x","volume":"21","author":"AJ Camm","year":"2022","unstructured":"Camm AJ, Sabbour H, Schnell O, Summaria F, Verma A. Managing thrombotic risk in patients with diabetes. Cardiovasc Diabetol. 2022;21(1):160.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1685_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/MCA.0000000000000547","volume":"29","author":"M Hamilos","year":"2018","unstructured":"Hamilos M, Petousis S, Xanthopoulou I, Goudevenos J, Kanakakis J, Sitafidis G, Vavouranakis M, Skalidis E, Kochiadakis G, Lekakis J, Vardas PE, Alexopoulos D. Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy. Coron Artery Dis. 2018;29(1):53\u20139.","journal-title":"Coron Artery Dis"},{"issue":"19","key":"1685_CR10","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.jacc.2021.03.298","volume":"77","author":"LA Leiter","year":"2021","unstructured":"Leiter LA, Bhatt DL, McGuire DK, Teoh H, Fox K, Simon T, Mehta SR, Lev EI, Kiss RG, Dalby AJ, Bueno H, Ridderstr\u00e5le W, Himmelmann A, Prats J, Liu Y, Lee JJ, Amerena J, Kosiborod MN, Steg PG, THEMIS Steering Committee and Investigators. Diabetes-related factors and the effects of ticagrelor plus aspirin in the THEMIS and THEMIS-PCI trials. J Am Coll Cardiol. 2021;77(19):2366\u201377.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1685_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12933-021-01416-1","volume":"20","author":"P Blin","year":"2021","unstructured":"Blin P, Darmon P, Henry P, Guiard E, Bernard MA, Dureau-Pournin C, Maizi H, Thomas-Delecourt F, Lassalle R, Droz-Perroteau C, Moore N. Patients with stable coronary artery disease and type 2 diabetes but without prior myocardial infarction or stroke and THEMIS-like patients: real-world prevalence and risk of major outcomes from the SNDS French nationwide claims database. Cardiovasc Diabetol. 2021;20(1):229.","journal-title":"Cardiovasc Diabetol"},{"issue":"22","key":"1685_CR12","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1161\/CIRCULATIONAHA.116.024710","volume":"134","author":"PA Gurbel","year":"2016","unstructured":"Gurbel PA, Jeong YH, Tantry US. The dogged search for cryptic effects of ticagrelor: wishful thinking or real benefits beyond P2Y12 inhibition? Circulation. 2016;134(22):1720\u20133.","journal-title":"Circulation"},{"issue":"1","key":"1685_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/cvr\/cvw233","volume":"113","author":"MF Reiner","year":"2017","unstructured":"Reiner MF, Akhmedov A, Stivala S, Keller S, Gaul DS, Bonetti NR, Savarese G, Glanzmann M, Zhu C, Ruf W, Yang Z, Matter CM, L\u00fcscher TF, Camici GG, Beer JH. Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression. Cardiovasc Res. 2017;113(1):61\u20139.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"1685_CR14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000347122","volume":"124","author":"K Torngren","year":"2013","unstructured":"Torngren K, Ohman J, Salmi H, Larsson J, Erlinge D. Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. Cardiology. 2013;124(4):252\u20138.","journal-title":"Cardiology"},{"issue":"5","key":"1685_CR15","doi-asserted-by":"publisher","first-page":"568","DOI":"10.21037\/cdt.2018.07.01","volume":"8","author":"M Hamilos","year":"2018","unstructured":"Hamilos M, Petousis S, Parthenakis F. Interaction between platelets and endothelium: from pathophysiology to new therapeutic options. Cardiovasc Diagn Ther. 2018;8(5):568\u201380.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"2","key":"1685_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/1074248411410883","volume":"17","author":"JJ van Giezen","year":"2012","unstructured":"van Giezen JJ, Sidaway J, Glaves P, Kirk I, Bj\u00f6rkman JA. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther. 2012;17(2):164\u201372.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"4","key":"1685_CR17","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.bbrc.2012.01.093","volume":"418","author":"J Ohman","year":"2012","unstructured":"Ohman J, Kudira R, Albinsson S, Olde B, Erlinge D. Ticagrelor induces adenosine triphosphate release from human red blood cells. Biochem Biophys Res Commun. 2012;418(4):754\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1685_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1074248413511693","volume":"19","author":"D Armstrong","year":"2014","unstructured":"Armstrong D, Summers C, Ewart L, Nylander S, Sidaway JE, van Giezen JJ. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther. 2014;19(2):209\u201319.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"23","key":"1685_CR19","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/j.jacc.2014.03.031","volume":"63","author":"M Cattaneo","year":"2014","unstructured":"Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014;63(23):2503\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1685_CR20","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jacc.2013.09.067","volume":"63","author":"L Bonello","year":"2014","unstructured":"Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, Gariboldi V, Condo J, Thuny F, Frere C, Camoin-Jau L, Paganelli F, Dignat-George F, Guieu R. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol. 2014;63(9):872\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1685_CR21","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/bph.13429","volume":"173","author":"S Nylander","year":"2016","unstructured":"Nylander S, Schulz R. Effects of P2Y12 receptor antagonists beyond platelet inhibition\u2013comparison of ticagrelor with thienopyridines. Br J Pharmacol. 2016;173(7):1163\u201378.","journal-title":"Br J Pharmacol"},{"issue":"11","key":"1685_CR22","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1161\/CIRCULATIONAHA.116.023743","volume":"134","author":"F Mangiacapra","year":"2016","unstructured":"Mangiacapra F, Panaioli E, Colaiori I, Ricottini E, Lauria Pantano A, Pozzilli P, Barbato E, Di Sciascio G. Clopidogrel versus ticagrelor for antiplatelet maintenance in diabetic patients treated with percutaneous coronary intervention: results of the CLOTILDIA study (clopidogrel high dose versus ticagrelor for antiplatelet maintenance in diabetic patients). Circulation. 2016;134(11):835\u20137.","journal-title":"Circulation"},{"issue":"16","key":"1685_CR23","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jcin.2017.05.064","volume":"10","author":"HS Jeong","year":"2017","unstructured":"Jeong HS, Hong SJ, Cho SA, Kim JH, Cho JY, Lee SH, Joo HJ, Park JH, Yu CW, Lim DS. Comparison of ticagrelor versus prasugrel for inflammation, vascular function, and circulating endothelial progenitor cells in diabetic patients with non-ST-segment elevation acute coronary syndrome requiring coronary stenting: a prospective, randomized, crossover trial. JACC Cardiovasc Interv. 2017;10(16):1646\u201358.","journal-title":"JACC Cardiovasc Interv"},{"issue":"6","key":"1685_CR24","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1160\/TH16-12-0973","volume":"117","author":"G Campo","year":"2017","unstructured":"Campo G, Vieceli Dalla Sega F, Pavasini R, Aquila G, Gallo F, Fortini F, Tonet E, Cimaglia P, Del Franco A, Pestelli G, Pecoraro A, Contoli M, Balla C, Biscaglia S, Rizzo P, Ferrari R. Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease. Thromb Haemost. 2017;117(6):1208\u201316.","journal-title":"Thromb Haemost"},{"issue":"16","key":"1685_CR25","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.jcin.2018.04.022","volume":"11","author":"S Ariotti","year":"2018","unstructured":"Ariotti S, Ortega-Paz L, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis KM, Rimoldi SF, Janssens G, Gianni U, van den Berge JC, Karagiannis A, Windecker S, Valgimigli M, HI-TECH Investigators. Effects of ticagrelor, prasugrel, or clopidogrel on endothelial function and\u00a0other vascular biomarkers: a randomized crossover study. JACC Cardiovasc Interv. 2018;11(16):1576\u201386.","journal-title":"JACC Cardiovasc Interv"},{"issue":"33","key":"1685_CR26","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1093\/eurheartj\/ehz917","volume":"41","author":"B Schnorbus","year":"2020","unstructured":"Schnorbus B, Daiber A, Jurk K, Warnke S, Koenig J, Lackner KJ, M\u00fcnzel T, Gori T. Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study. Eur Heart J. 2020;41(33):3144\u201352.","journal-title":"Eur Heart J"},{"key":"1685_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.820604","volume":"8","author":"B Guan","year":"2021","unstructured":"Guan B, Zhao L, Ma D, Fan Y, Zhang H, Wang A, Xu H. The effect of ticagrelor on endothelial function compared to prasugrel, clopidogrel, and placebo: a systematic review and meta-analysis. Front Cardiovasc Med. 2021;8:820604.","journal-title":"Front Cardiovasc Med"},{"issue":"19","key":"1685_CR28","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1016\/j.jcin.2020.07.032","volume":"13","author":"G Ndrepepa","year":"2020","unstructured":"Ndrepepa G, Kastrati A, Menichelli M, Neumann FJ, W\u00f6hrle J, Bernlochner I, Richardt G, Witzenbichler B, Sibbing D, Gewalt S, Angiolillo DJ, Hamm CW, Hapfelmeier A, Trenk D, Laugwitz KL, Schunkert H, Sch\u00fcpke S, Mayer K. Ticagrelor or prasugrel in patients with acute coronary syndromes and diabetes mellitus. JACC Cardiovasc Interv. 2020;13(19):2238\u201347.","journal-title":"JACC Cardiovasc Interv"},{"issue":"19","key":"1685_CR29","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1016\/j.jacc.2020.03.008","volume":"75","author":"DJ Angiolillo","year":"2020","unstructured":"Angiolillo DJ, Baber U, Sartori S, Briguori C, Dangas G, Cohen DJ, Mehta SR, Gibson CM, Chandiramani R, Huber K, Kornowski R, Weisz G, Kunadian V, Oldroyd KG, Ya-Ling H, Kaul U, Witzenbichler B, Dudek D, Sardella G, Escaned J, Sharma S, Shlofmitz RA, Collier T, Pocock S, Mehran R. Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2020;75(19):2403\u201313.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1685_CR30","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/j.1538-7836.2007.02356.x","volume":"5","author":"M Cattaneo","year":"2007","unstructured":"Cattaneo M, Lecchi A. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost. 2007;5(3):577\u201382.","journal-title":"J Thromb Haemost"},{"issue":"39","key":"1685_CR31","doi-asserted-by":"publisher","first-page":"15782","DOI":"10.1073\/pnas.1218880110","volume":"10","author":"NS Kirkby","year":"2013","unstructured":"Kirkby NS, Lundberg MH, Chan MV, Vojnovic I, Solomon AB, Emerson M, Mitchell JA, Warner TD. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide. Proc Natl Acad Sci U S A. 2013;10(39):15782\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1685_CR32","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/bcp.12826","volume":"81","author":"MV Chan","year":"2016","unstructured":"Chan MV, Knowles RB, Lundberg MH, Tucker AT, Mohamed NA, Kirkby NS, Armstrong PC, Mitchell JA, Warner TD. P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation. Br J Clin Pharmacol. 2016;81(4):621\u201333.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1685_CR33","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1160\/TH07-07-0478","volume":"99","author":"D Sibbing","year":"2008","unstructured":"Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Sch\u00f6mig A, Kastrati A, von Beckerath N. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost. 2008;99(1):121\u20136.","journal-title":"Thromb Haemost"},{"issue":"6","key":"1685_CR34","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3109\/09537104.2014.974527","volume":"26","author":"B Chyrchel","year":"2015","unstructured":"Chyrchel B, Toto\u0144-\u017bura\u0144ska J, Kruszelnicka O, Chyrchel M, Mielecki W, Ko\u0142ton-Wr\u00f3\u017c M, Wo\u0142kow P, Surdacki A. Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: a preliminary report. Platelets. 2015;26(6):593\u20137.","journal-title":"Platelets"},{"issue":"9","key":"1685_CR35","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00726-015-1976-3","volume":"47","author":"O Kruszelnicka","year":"2015","unstructured":"Kruszelnicka O, Chyrchel B, Golay A, Surdacki A. Differential associations of circulating asymmetric dimethylarginine and cell adhesion molecules with metformin use in patients with type 2 diabetes mellitus and stable coronary artery disease. Amino Acids. 2015;47(9):1951\u20139.","journal-title":"Amino Acids"},{"issue":"7","key":"1685_CR36","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jacc.2010.09.050","volume":"57","author":"G Patti","year":"2011","unstructured":"Patti G, Grieco D, Dicuonzo G, Pasceri V, Nusca A, Di Sciascio G. High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) randomized study. J Am Coll Cardiol. 2011;57(7):771\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"1685_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijcard.2017.06.099","volume":"248","author":"TK Rudolph","year":"2017","unstructured":"Rudolph TK, Fuchs A, Klinke A, Schlichting A, Friedrichs K, Hellmich M, Mollenhauer M, Schwedhelm E, Baldus S, Rudolph V. Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet-leukocyte interaction in patients with unstable angina pectoris: a randomized controlled trial. Int J Cardiol. 2017;248:7\u201313.","journal-title":"Int J Cardiol"},{"issue":"8","key":"1685_CR38","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.2337\/diabetes.54.8.2430","volume":"54","author":"DJ Angiolillo","year":"2005","unstructured":"Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ram\u00edrez C, Sabat\u00e9 M, Jimenez-Quevedo P, Hern\u00e1ndez R, Moreno R, Escaned J, Alfonso F, Ba\u00f1uelos C, Costa MA, Bass TA, Macaya C. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54(8):2430\u20135.","journal-title":"Diabetes"},{"issue":"9","key":"1685_CR39","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jacc.2008.05.031","volume":"52","author":"S Guthikonda","year":"2008","unstructured":"Guthikonda S, Alviar CL, Vaduganathan M, Arikan M, Tellez A, DeLao T, Granada JF, Dong JF, Kleiman NS, Lev EI. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol. 2008;52(9):743\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1685_CR40","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/labinvest.3780446","volume":"82","author":"WA Muller","year":"2002","unstructured":"Muller WA. Leukocyte-endothelial cell interactions in the inflammatory response. Lab Invest. 2002;82(5):521\u201333.","journal-title":"Lab Invest"},{"issue":"12","key":"1685_CR41","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1161\/hc3701.095949","volume":"104","author":"S Blankenberg","year":"2001","unstructured":"Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 2001;104(12):1336\u201342.","journal-title":"Circulation"},{"issue":"9","key":"1685_CR42","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1161\/01.CIR.101.9.948","volume":"101","author":"JA Suwaidi","year":"2000","unstructured":"Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101(9):948\u201354.","journal-title":"Circulation"},{"issue":"16","key":"1685_CR43","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1161\/01.CIR.101.16.1899","volume":"101","author":"V Sch\u00e4chinger","year":"2000","unstructured":"Sch\u00e4chinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101(16):1899\u2013906.","journal-title":"Circulation"},{"key":"1685_CR44","doi-asserted-by":"crossref","unstructured":"Vials A, Burnstock G. A2-purinoceptor-mediated relaxation in the guinea-pig coronary vasculature: a role for nitric oxide. Br J Pharmacol. 1993;109(2):424\u20139.","DOI":"10.1111\/j.1476-5381.1993.tb13586.x"},{"issue":"8","key":"1685_CR45","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1161\/01.CIR.92.8.2135","volume":"92","author":"P Smits","year":"1995","unstructured":"Smits P, Williams SB, Lipson DE, Banitt P, Rongen GA, Creager MA. Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans. Circulation. 1995;92(8):2135\u201341.","journal-title":"Circulation"},{"issue":"2 Pt 1","key":"1685_CR46","doi-asserted-by":"publisher","first-page":"C522","DOI":"10.1152\/ajpcell.1996.270.2.C522","volume":"270","author":"MG Bouma","year":"1996","unstructured":"Bouma MG, van den Wildenberg FA, Buurman WA. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am J Physiol. 1996;270(2 Pt 1):C522\u20139.","journal-title":"Am J Physiol"},{"issue":"11","key":"1685_CR47","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1161\/01.ATV.19.11.2673","volume":"19","author":"G Walker","year":"1999","unstructured":"Walker G, Langheinrich AC, Dennhauser E, Bohle RM, Dreyer T, Kreuzer J, Tillmanns H, Braun-Dullaeus RC, Haberbosch W. 3-deazaadenosine prevents adhesion molecule expression and atherosclerotic lesion formation in the aortas of C57BL\/6J mice. Arterioscler Thromb Vasc Biol. 1999;19(11):2673\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"1685_CR48","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/jcp.24568","volume":"229","author":"SM Hassanian","year":"2014","unstructured":"Hassanian SM, Dinarvand P, Rezaie AR. Adenosine regulates the proinflammatory signaling function of thrombin in endothelial cells. J Cell Physiol. 2014;229(9):1292\u2013300.","journal-title":"J Cell Physiol"},{"key":"1685_CR49","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.yjmcc.2019.01.004","volume":"128","author":"B Kutryb-Zaj\u0105c","year":"2019","unstructured":"Kutryb-Zaj\u0105c B, Mierzejewska P, Sucajtys-Szulc E, Buli\u0144ska A, Zabielska MA, Jab\u0142o\u0144ska P, Serocki M, Kosza\u0142ka P, Milczarek R, Jasztal A, Bartoszewski R, Ch\u0142opicki S, S\u0142omi\u0144ska EM, Smole\u0144ski RT. Inhibition of LPS-stimulated ecto-adenosine deaminase attenuates endothelial cell activation. J Mol Cell Cardiol. 2019;128:62\u201376.","journal-title":"J Mol Cell Cardiol"},{"issue":"3","key":"1685_CR50","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/jth.14689","volume":"18","author":"A G\u0105secka","year":"2020","unstructured":"G\u0105secka A, Nieuwland R, Budnik M, Dignat-George F, Eyileten C, Harrison P, Lacroix R, Leroyer A, Opolski G, Pluta K, van der Pol E, Postu\u0142a M, Siljander P, Siller-Matula JM, Filipiak KJ. Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel. J Thromb Haemost. 2020;18(3):609\u201323.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"1685_CR51","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7150\/ijms.28580","volume":"16","author":"B Chyrchel","year":"2019","unstructured":"Chyrchel B, Dro\u017cd\u017c A, D\u0142ugosz D, St\u0119pie\u0144 E, Surdacki A. Platelet reactivity and circulating platelet-derived microvesicles are differently affected by P2Y12 receptor antagonists. Int J Med Sci. 2019;16(2):264\u201375.","journal-title":"Int J Med Sci"},{"issue":"12","key":"1685_CR52","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1182\/blood.V77.12.2641.2641","volume":"77","author":"G Tans","year":"1991","unstructured":"Tans G, Rosing J, Thomassen MC, Heeb MJ, Zwaal RF, Griffin JH. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood. 1991;77(12):2641\u20138.","journal-title":"Blood"},{"issue":"1","key":"1685_CR53","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.thromres.2008.06.006","volume":"123","author":"S Nomura","year":"2008","unstructured":"Nomura S, Ozaki Y, Ikeda Y. Function and role of microparticles in various clinical settings. Thromb Res. 2008;123(1):8\u201323.","journal-title":"Thromb Res"},{"key":"1685_CR54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3389\/fphar.2016.00293","volume":"7","author":"L Badimon","year":"2016","unstructured":"Badimon L, Suades R, Fuentes E, Palomo I, Padr\u00f3 T. Role of platelet-derived microvesicles as crosstalk mediators in atherothrombosis and future pharmacology targets: a link between inflammation, atherosclerosis, and thrombosis. Front Pharmacol. 2016;7:293.","journal-title":"Front Pharmacol"},{"key":"1685_CR55","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3389\/fcvm.2017.00074","volume":"4","author":"MTK Zaldivia","year":"2017","unstructured":"Zaldivia MTK, McFadyen JD, Lim B, Wang X, Peter K. Platelet-derived microvesicles in cardiovascular diseases. Front Cardiovasc Med. 2017;4:74.","journal-title":"Front Cardiovasc Med"},{"issue":"5\u20136","key":"1685_CR56","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10557-017-6757-7","volume":"31","author":"J Rosi\u0144ska","year":"2017","unstructured":"Rosi\u0144ska J, \u0141ukasik M, Kozubski W. The impact of vascular disease treatment on platelet-derived microvesicles. Cardiovasc Drugs Ther. 2017;31(5\u20136):627\u201344.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"1685_CR57","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1172\/JCI2592","volume":"102","author":"OP Barry","year":"1998","unstructured":"Barry OP, Pratic\u00f2 D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest. 1998;102(1):136\u201344.","journal-title":"J Clin Invest"},{"issue":"7","key":"1685_CR58","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1161\/01.ATV.0000170133.43608.37","volume":"25","author":"SF Mause","year":"2005","unstructured":"Mause SF, von Hundelshausen P, Zernecke A, Koenen RR, Weber C. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol. 2005;25(7):1512\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"1685_CR59","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1160\/TH16-11-0837","volume":"117","author":"C Christersson","year":"2017","unstructured":"Christersson C, Thulin \u00c5, Siegbahn A. Microparticles during long-term follow-up after acute myocardial infarction. Association to atherosclerotic burden and risk of cardiovascular events. Thromb Haemost. 2017;117(8):1571\u201381.","journal-title":"Thromb Haemost"},{"issue":"6","key":"1685_CR60","doi-asserted-by":"publisher","first-page":"782","DOI":"10.5603\/CJ.a2018.0045","volume":"26","author":"A G\u0105secka","year":"2019","unstructured":"G\u0105secka A, Nieuwland R, van der Pol E, Hajji N, \u0106wiek A, Pluta K, Konwerski M, Filipiak KJ. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets. Cardiol J. 2019;26(6):782\u20139.","journal-title":"Cardiol J"},{"issue":"24","key":"1685_CR61","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.ehj.2003.08.021","volume":"24","author":"AD Blann","year":"2003","unstructured":"Blann AD, Nadar SK, Lip GYH. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J. 2003;24(24):2166\u201379.","journal-title":"Eur Heart J"},{"key":"1685_CR62","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1161\/01.ATV.0000215951.36219.a4","volume":"26","author":"J de J\u00e4ger","year":"2006","unstructured":"de J\u00e4ger J, Dekker JM, Kooy A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study. Arterioscler Thromb Vasc Biol. 2006;26(5):1086\u201393.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1685_CR63","doi-asserted-by":"crossref","unstructured":"Teerlink T, Heine RJ, Nijpels G, Bouter LM, Stehouwer CDA, Dekker JM. Asymmetric dimethylarginine (ADMA) is associated with incident cardiovascular disease in the general population. The Hoorn study. Atheroscler Suppl. 2006;7(3):23 (Abstract).","DOI":"10.1016\/S1567-5688(06)80065-6"},{"key":"1685_CR64","doi-asserted-by":"publisher","first-page":"846","DOI":"10.2337\/dc13-0546","volume":"37","author":"M Anderssohn","year":"2014","unstructured":"Anderssohn M, McLachlan S, L\u00fcneburg N, Robertson C, Schwedhelm E, Williamson RM, Strachan MW, Ajjan R, Grant PJ, B\u00f6ger RH, Price JF. Genetic and environmental determinants of dimethylarginines and association with cardiovascular disease in patients with type 2 diabetes. Diabetes Care. 2014;37(3):846\u201384.","journal-title":"Diabetes Care"},{"key":"1685_CR65","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1161\/CIRCULATIONAHA.108.838268","volume":"119","author":"RH B\u00f6ger","year":"2009","unstructured":"B\u00f6ger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, Schulze F, Xanthakis V, Benndorf RA, Vasan RS. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation. 2009;119(12):1592\u2013600.","journal-title":"Circulation"},{"key":"1685_CR66","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ijcard.2011.06.120","volume":"153","author":"TM Lu","year":"2011","unstructured":"Lu TM, Chung MY, Lin MW, Hsu CP, Lin SJ. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. Int J Cardiol. 2011;153(2):135\u201340.","journal-title":"Int J Cardiol"},{"issue":"10","key":"1685_CR67","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1161\/CIRCULATIONAHA.108.838169","volume":"120","author":"K Szummer","year":"2009","unstructured":"Szummer K, Lundman P, Jacobson SH, Sch\u00f6n S, Lindb\u00e4ck J, Stenestrand U, Wallentin L, Jernberg T, for SWEDEHEART. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation. 2009;120(10):851\u20138.","journal-title":"Circulation"},{"issue":"5","key":"1685_CR68","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.amjcard.2006.09.112","volume":"99","author":"AC Salisbury","year":"2007","unstructured":"Salisbury AC, Reid KJ, Spertus JA. Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes. Am J Cardiol. 2007;99(5):636\u201341.","journal-title":"Am J Cardiol"},{"issue":"11","key":"1685_CR69","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.amjcard.2009.07.014","volume":"104","author":"P Morillas","year":"2009","unstructured":"Morillas P, Quiles J, Cordero A, Guindo J, Soria F, Maz\u00f3n P, Gonzalez-Juanatey JR, Bertomeu V, Prevalence of Peripheral Arterial Disease in Patients With Acute Coronary Syndrome (PAMISCA) Investigators. Impact of clinical and subclinical peripheral arterial disease in mid-term prognosis of patients with acute coronary syndrome. Am J Cardiol. 2009;104(11):1494\u20138.","journal-title":"Am J Cardiol"},{"key":"1685_CR70","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.08.004","volume":"193","author":"RB Knowles","year":"2019","unstructured":"Knowles RB, Warner TD. Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy. Pharmacol Ther. 2019;193:83\u201390.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"1685_CR71","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/j.1476-5381.1987.tb11367.x","volume":"92","author":"MW Radomski","year":"1987","unstructured":"Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 1987;92(3):639\u201346.","journal-title":"Br J Pharmacol"},{"issue":"16","key":"1685_CR72","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","volume":"381","author":"S Sch\u00fcpke","year":"2019","unstructured":"Sch\u00fcpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, W\u00f6hrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Fl\u00fcgel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, M\u00f6llmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S, Allali A, Ndrepepa G, Sch\u00fchlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A, T\u00f6lg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A, ISAR-REACT 5 Trial Investigators. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381(16):1524\u201334.","journal-title":"N Engl J Med"},{"issue":"10204","key":"1685_CR73","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S0140-6736(19)31887-2","volume":"394","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstr\u00e5le W, Chen J, Song Y, Diaz R, Goto S, James SK, Ray KK, Parkhomenko AN, Kosiborod MN, McGuire DK, Harrington RA, THEMIS Steering Committee and Investigators. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019;394(10204):1169\u201380.","journal-title":"Lancet"},{"key":"1685_CR74","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3389\/fphys.2018.00337","volume":"9","author":"F Vieceli Dalla Sega","year":"2018","unstructured":"Vieceli Dalla Sega F, Fortini F, Aquila G, Pavasini R, Biscaglia S, Bernucci D, Del Franco A, Tonet E, Rizzo P, Ferrari R, Campo G. Ticagrelor improves endothelial function by decreasing circulating epidermal growth factor (EGF). Front Physiol. 2018;9:337.","journal-title":"Front Physiol"},{"issue":"5","key":"1685_CR75","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.3390\/ijms21051576","volume":"21","author":"G Aquila","year":"2020","unstructured":"Aquila G, Vieceli Dalla Sega F, Marracino L, Pavasini R, Cardelli LS, Piredda A, Scoccia A, Martino V, Fortini F, Bononi I, Martini F, Manfrini M, Pannuti A, Ferrari R, Rizzo P, Campo G. Ticagrelor increases SIRT1 and HES1 mRNA levels in peripheral blood cells from patients with stable coronary artery disease and chronic obstructive pulmonary disease. Int J Mol Sci. 2020;21(5):1576.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1685_CR76","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1161\/ATVBAHA.121.317513","volume":"42","author":"CF Tam","year":"2022","unstructured":"Tam CF, Chan YH, Wong YK, Li Z, Zhu X, Su KJ, Ganguly A, Hwa K, Ling XB, Tse HF. Multi-omics signatures link to ticagrelor effects on vascular function in patients with acute coronary syndrome. Arterioscler Thromb Vasc Biol. 2022;42(6):789\u201398.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"21","key":"1685_CR77","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","volume":"381","author":"R Mehran","year":"2019","unstructured":"Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, D\u017eav\u00edk V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta SR, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S, Gibson CM. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381(21):2032\u201342.","journal-title":"N Engl J Med"},{"key":"1685_CR78","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.atherosclerosis.2020.01.002","volume":"295","author":"P Chichareon","year":"2020","unstructured":"Chichareon P, Modolo R, Kogame N, Takahashi K, Chang CC, Tomaniak M, Botelho R, Eeckhout E, Hofma S, Trendafilova-Lazarova D, K\u0151szegi Z, I\u00f1iguez A, Wykrzykowska JJ, Piek JJ, Garg S, Hamm C, Steg PG, J\u00fcni P, Vranckx P, Valgimigli M, Windecker S, Onuma Y, Serruys PW. Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. Atherosclerosis. 2020;295:45\u201353.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1685_CR79","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12933-020-01153-x","volume":"19","author":"C Gao","year":"2020","unstructured":"Gao C, Tomaniak M, Takahashi K, Kawashima H, Wang R, Hara H, Ono M, Montalescot G, Garg S, Haude M, Slagboom T, Vranckx P, Valgimigli M, Windecker S, van Geuns RJ, Hamm C, Steg PG, Onuma Y, Angiolillo DJ, Serruys PW. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Cardiovasc Diabetol. 2020;19(1):179.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"1685_CR80","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1538-7836.2010.04160.x","volume":"9","author":"PCJ Armstrong","year":"2011","unstructured":"Armstrong PCJ, Leadbeater PD, Chan MV, Kirkby NS, Jakubowski JA, Mitchell JA, Warner TD. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost. 2011;9(3):552\u201361.","journal-title":"J Thromb Haemost"},{"key":"1685_CR81","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1111\/j.1538-7836.2011.04453.x","volume":"9","author":"NS Kirkby","year":"2011","unstructured":"Kirkby NS, Leadbeater PD, Chan MV, Nylander S, Mitchell JA, Warner TD. Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haemost. 2011;9(10):2103\u20135.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"1685_CR82","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1172\/JCI110814","volume":"71","author":"GA FitzGerald","year":"1983","unstructured":"FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ 2nd, Lawson JA, Brash AR. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71(3):676\u201388.","journal-title":"J Clin Invest"},{"issue":"3","key":"1685_CR83","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11302-011-9220-4","volume":"7","author":"HA Johnston-Cox","year":"2011","unstructured":"Johnston-Cox HA, Ravid K. Adenosine and blood platelets. Purinergic Signal. 2011;7(3):357\u201365.","journal-title":"Purinergic Signal"},{"issue":"4","key":"1685_CR84","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1538-7836.2012.04639.x","volume":"10","author":"JM Siller-Matula","year":"2012","unstructured":"Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, Jilma B. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost. 2012;10(4):529\u201342.","journal-title":"J Thromb Haemost"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01685-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-022-01685-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01685-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T16:05:51Z","timestamp":1668787551000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-022-01685-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1685"],"URL":"https:\/\/doi.org\/10.1186\/s12933-022-01685-4","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]},"assertion":[{"value":"1 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Bioethical Committee of our university (Approval numbers: KBET\/277\/B\/2013 and 1072.6120.143.2019 issued on November 28th, 2013 and May 30th, 2019, respectively) and written informed consent was obtained from the study subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"249"}}